Werewolf Therapeutics (HOWL) versus Its Competitors Critical Analysis

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Werewolf Therapeutics to similar businesses based on the strength of its profitability, risk, institutional ownership, analyst recommendations, valuation, dividends and earnings.

Risk & Volatility

Werewolf Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics’ rivals have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.

Valuation and Earnings

This table compares Werewolf Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Werewolf Therapeutics $1.88 million -$60.82 million -1.56
Werewolf Therapeutics Competitors $713.94 million $9.18 million -17.98

Werewolf Therapeutics’ rivals have higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and price targets for Werewolf Therapeutics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics 1 4 1 0 2.00
Werewolf Therapeutics Competitors 9959 15361 45766 1602 2.54

Werewolf Therapeutics presently has a consensus price target of $2.50, indicating a potential upside of 167.38%. As a group, “Biotechnology” companies have a potential upside of 114.70%. Given Werewolf Therapeutics’ higher probable upside, research analysts clearly believe Werewolf Therapeutics is more favorable than its rivals.

Insider & Institutional Ownership

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Werewolf Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Werewolf Therapeutics N/A -187.29% -57.88%
Werewolf Therapeutics Competitors -12,519.20% -215.47% -31.42%

Summary

Werewolf Therapeutics beats its rivals on 7 of the 13 factors compared.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body’s immune response against tumors. The company’s INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.